 The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Incs NASDAQ: MRTX adagrasib in non-small cell lung cancer NSCLC patients with the KRAS-G12C mutation. The decision was based on preliminary results from the Phase 12 KRYSTAL-01 trial in patients with advanced NSCLC whose cancer had progressed following prior treatment with immunotherapy or chemotherapy. 